LENZ LENZ Therapeutics
- 18.540
- -0.090-0.48%
- 18.000
- -0.540-2.91%
LENZ Therapeutics News
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Monday.Shares of ICC Holdings, Inc. (NASDAQ:ICCH) rose sharply during Monday's session.Mutual Capital Group announced plans to a
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a late clinical-stage biopharmaceutical company focused on developing the first aceclid
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400
Sarepta Therapeutics (SRPT) is set to replace Shockwave Medical (SWAV) in the S&P MidCap 400 effective June 3, according to a late Wednesday statement from S&P Dow Jones Indices. Johnson & Johnson (JN
Cutia Therapeutics' Atopic Dermatitis Drug Advances
United States Sex Reassignment Hormone Therapy Research Report 2024 Featuring Viatris, AbbVie, ASCEND Therapeutics, Pfizer, Eli Lilly and Co, Novartis, Endo International
Enlivex Therapeutics Announces New Securities Deal
Sarepta Therapeutics To Join S&P Midcap 400, Effective June 3
Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson is acquiring Shockwave Medi
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
TransCode Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 79.64% HC Wainwright & Co. $3 → $3 Reiterates Buy → Buy 05/16/2024 79.64% HC Wainwright & Co. →
Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights
In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:ANIK), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasin
Investing in United Therapeutics (NASDAQ:UTHR) Five Years Ago Would Have Delivered You a 213% Gain
Express News | TransCode Therapeutics Reports Data From First-in-Human Clinical Study Using TTX-MC138
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Throughout the last three months, 17 analysts have evaluated Sage Therapeutics (NASDAQ:SAGE), offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent ratings
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ:CORT), offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments, the tab
Express News | Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting
Express News | PureTech Health Announces Merger Agreement Between Akili and Virtual Therapeutics to Form Leading Digital Health Company
Express News | Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN
Analysis
Price Target
No Data
